Our company has signed a tripartite memorandum of cooperation with Nanjing Xinbai Pharmaceutical Co., Ltd. and Jiangxi Rongchang Pharmaceutical Trade Co., Ltd. to jointly develop the market for Iron Dextran Injection products.
"Composition and administration method for upper respiratory drug delivery" has been granted an Australian invention patent.
"Composition and administration method for upper respiratory drug delivery" has been granted a Japanese invention patent.
The stock is listed in the emerging market for trading. 。
The OBM-B01 cyanide compound drug development project has been granted the Republic of China (Taiwan) Invention Patent No. I818601, titled "Composition for Upper Respiratory Tract Administration and Its Applications," by the Intellectual Property Office of the Ministry of Economic Affairs, Republic of China.
The application of the "Chelating Complex Micelle" technology for the Ministry of Economic Affairs' Small Business Innovation Research (SBIR) program, titled "Development Plan for Complex Micelle Ultrasound Contrast Agent," has been reviewed and approved.
The application for the Ministry of Economic Affairs Small Business Innovation Research (SBIR) program, titled "Development Project of Sustained-Release Composite Micelle Diabetes Medication," was reviewed and approved in October 2019.
The "Nanocomposite Micelle" patented technology has been approved by the Japan Patent Office (JPO) under application number 特願 2016-132358, titled "Drug Carrier with Chelating Composite Micelles and Use Thereof."
1. The "Nanocomposite Micelle" technology has been granted a patent certificate by the Israel Patent Office (ILPO) with the Israeli patent number IL 232938, titled "A pharmaceutical composition used for reducing damage caused by free radicals."
2. The "Nanocomposite Micelle" patented technology has been approved by the European Patent Office (EPO) under application number 12851387.6, titled "A Drug Carrier with Chelating Complex Micelles and the Application Thereof."
The location has been relocated from 2F, No. 6, Lane 31, Section 1, Huan-Dong Road, Tainan Science Park, Xinshi District, Tainan City, to 2F-1, No. 9, Nanke 2nd Road, Tainan Science Park, Xinshi District, Tainan City.
Issued by the United States Patent and Trademark Office (USPTO), Patent Certificate No. US9700623 for the invention titled "Pharmaceutical Composition Used for Reducing Damage Caused by Free Radicals."
1.Issued by the United States Patent and Trademark Office (USPTO), Patent Certificate No. US9,597,406 for the invention titled "Controlled Release Method for a Pharmaceutical Composition Composed of Chelating Complex Micelles."
2.Issued by the Korean Intellectual Property Office (KIPO), Patent Certificate No. 10-1730057 for the invention titled "A Pharmaceutical Composition Used for Reducing Damage Caused by Free Radicals."
Issued by the Intellectual Property Office of the Ministry of Economic Affairs of the Republic of China, Patent Certificate No. I568453 for the invention titled "Drug Carrier with Chelating Complex Micelles and Its Applications," and Patent Certificate No. I568454 for the invention titled "Triggered Release Method of Metal-Containing Composite Micellar Drug Carriers." Both patents are officially certified.
Issued by the Canadian Intellectual Property Office (CIPO), Patent Certificate No. CA2856501 for the invention titled "A Drug Carrier with Chelating Complex Micelles and the Application Thereof."
Issued by the Intellectual Property Office of the Ministry of Economic Affairs of the Republic of China, Patent Certificate No. I555532 for the invention titled "Pharmaceutical Composition of a Composite Micellar Carrier for Reducing Free Radical Damage."
Received Chinese patent CN103127521B, issued by the National Intellectual Property Administration of the People's Republic of China, for 'Drug carrier with chelating complex micelles and its application.'
Received Australian patent AU2012343239, issued by IP Australia, for 'A Drug Carrier with Chelating Complex Micelles and the Application Thereof.'
Received Korean patent 10-1628586, issued by the Korean Intellectual Property Office (KIPO), for 'The Controlled Release Method for a Pharmaceutical Composition Composed of Chelating Complex Micelles.'
Received a Japanese patent, Patent No. 5920955, issued by the Japan Patent Office (JPO) for 'Pharmaceutical composition for reducing damage caused by free radicals.'
Received three patents issued by the United States Patent and Trademark Office (USPTO) for 'Method of manufacturing a pharmaceutical composition having chelating type complex micelles,' 'Pharmaceutical composition of chelating complex micelles,' and 'Chelating complex micelles drug carrier.'
The research and development project for a radiation injury prevention drug (OBM-A01) has passed the human clinical trial review (Investigational New Drug, IND) by the U.S. Food and Drug Administration (FDA).
Received the Breaking Out of the Shell Award and the New Business Quality Award from the Small and Medium Enterprises Division of the Ministry of Economic Affairs.
Public offering.
The U.S. Patent and Trademark Office (USPTO) issued a U.S. 8785569 "Drug Carrier with Chelating Complex Micelles and the Application thereof" patent.
"OBM-A01" R&D case for drug project consulting and counseling, selected by the Food and Drug Administration of the Ministry of Health and Welfare, and included in the "Drug Regulatory Scientific Consultation and Counseling Index Case (IDX)" by the Pharmaceutical Inspection Center of the Ministry of Health and Welfare.
Moved from the Incubation Center to the 2nd Floor, No. 6, Lane 31, Section 1, Huandong Road, New Urban District, Tainan City.
Obtained approval from the Southern Taiwan Science Park Administration to invest and establish in the Southern Taiwan Science Park.
Presented CCM drug carrier technology at the 2013 BIO International Convention.
We applied for and approved the Small Business Innovation R&D Program (SBIR) of the Ministry of Economic Affairs.
The organization was changed to Original BioMedical Co., Ltd.
Established and registered in the SMESA Incubator At Tainan Science Park, and the company name was Original BioMedical Ltd.
